Representative Publications

Sneh A, Deol YS, Ganju A, Shilo K, Rosol TJ, Nasser MW, Ganju RK. Differential role of Psoriasin (S100A7) in Estrogen Receptor aPositive and Negative breast cancer cells occur through Actin remodeling. Breast Cancer Research and Treatment 2013;138(3):727-39. PMID:23535840

Appakkudal R Anand, Helong Zhao, Tirumuru Nagaraja, Lisa A Robinson, Ganju RK. N-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton. Retrovirology 2013;10:2. PMID: 23294842

Tirumuru N, Chen L, Balasubramanian A, Groopman JE, Brigstock D, Anand A, Ganju RK. Connective Tissue Growth Factor Mediates Transforming Growth Factor β-Induced Fibrosis in Hepatitis C Virus-Infected Hepatocytes. PlosOne 2012;7(10):e46526.

Tirumuru N, Anand AR, Zhao H, and Ganju RK. SLP-76 regulates HIV-1 infection in T-cells through a Nef-dependent mechanism. J Immunol. 2012 15;188(6):2769-77.

Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai XF. Melanoma Cell Expression of CD200 Inhibits Tumor Formation and Lung Metastasis via Inhibition of Myeloid Cell Functions. PLoS One. 2012;7(2):e31442. PMID:22319630

Nasser MW, Qamri Z, Deol YS, Shilo K, Leone G, Bai X-F, Zou X, Wolf R, Yuspa S, Ganju RK. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012;1;72(3):604-15. PMID:22158945

Deol YS, Nasser MW, Yu L, Zou X, Ganju RK. Tumor suppressive effects of psoriasin (S100A7) are mediated through β-catenin/TCF4 pathway in estrogen receptor positive breast cancer cells. J Biol Chem 2011; 286(52):44845-54. PMID:22016394

Anand AR, Tirumuru N, and Ganju RK. A novel role for Slit2/Robo1 axis in modulating HIV-1 replication in T-cells. AIDS. 2011;31(16):3457-71. PMID: 21857494 

Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, and Ganju RK. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. 2011 PloS One 2011;6(9):e23901. PMID 21915267.

Wu Y, Jin Y, Feng X, Wu Z, Hankey W, Paisie C, Liu F, Barsky SH, Shang W, Ganju R, Zou X. The dietary phytochemical indole-3-carbinol induces Cdc25A degradation and inhibits the growth of human breast cancer cells. Cancer Prevention Research. 2010; 3(7):818-28. PMID 20587702

Tamama K, Kawasaki H, J, Ganju RK, Sen CK. Differential roles of hypoxia inducible factor subunits in multipotential stromal cells under hypoxic condition. Journal of Cellular Biochemistry. 2011;112(3):804-17. PMID: 21328454.

Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman J, Ganju RK. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Prevention Research 2011 4(1):65-75. PMID: 21097714

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8(11):3117-29. PMID: 19887554

Anand AR, Prasad A, Bradley RR, Deol YS, Nagaraja T, Ren X, Terwilliger EF, Ganju RK. HIV-gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood. 2009;114(17):3588-600. PMID: 19700666

Anand AR, Bradley R, Ganju RK. LPS-induced MCP-1 expression in human microvascular endothelial cells is mediated by the tyrosine kinase, Pyk2 via the p38 MAPK/NF-kappaB-dependent pathway. Mol Immunol. 2009. 46:962-968. PMID: 18954908

Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK. Slit-2 induces a tumor suppressive effect by regulating beta -catenin in breast cancer cells. J Biol Chem. 2008; 283:26624

Preet A, Groopman JE and Ganju RK. Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in-vitro as well as its growth and metastasis in-vivo. Oncogene. 2008; 27:339.

Anand AR, Cucchiarini M, Terwilliger EF and Ganju RK. The tyrosine kinase Pyk2 mediates lipopolysaccharide-induced Il-8 expression in human endothelial cells. J. Immunol. 2008; 180(8):5636.

Paruchuri P, Prasad P, McHugh K, Polyak K, and Ganju RK. S100A7-downregulation Inhibits EGFR-Induced Signaling in Breast Cancer Cells and Blocks Osteoclast Formation. PLoS ONE. 2008; 3 (3):e1741.

Gupta1 AT. Guerin-Peyrou G, Sharma GG, Park C, Agarwal M, Ganju RK , Choi1 K, Sukumar S, Pandita R, Ludwig and Pandita TK: Mammalian Ortholog of Drosophila MOF that Acetylates Histone H4 Lysine16 is Essential for Embryogenesis and Oncogenesis. Mol Cell Biol. 2008; 28(1):397-409.

Prasad A, Wu J and Ganju RK. “Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells”. J Leukoc Biol. 2007; 82(3):465-76.

Balasubramanian A, Koziel M, Groopman JE and Ganju RK. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis. 2006; 194:670-81.

Ghosh S, Preet A, Groopman JE, Ganju RK. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol. 2006; 43:2169-79.

Lane HC, Anand AR, Ganju RK. Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis. Int Immunol. 2006:18:1315-25.

Anand AR and Ganju RK. HIV gp120-mediated apoptosis of T-cells is regulated by membrane tyrosine phosphotase CD45. J Biol Chem. 2006 5;281(18):12289-99.















Ramesh Ganju, Ph.D.
Scott Endowed Chair and Professor
Vice Chair, Experimental Pathology

810 Biomedical Research Tower
460 West 12th Avenue
Columbus, OH 43210
Ph. 614-292-5539
Fax. 614-247-0051






Research Areas

The major focus of our lab is to determine the role of chemokines, especially CXCL12, and various inflammatory molecules, such as S100A7, and anti-inflammatory molecules, such as Slit2 and cannabinoids, in pathogenesis of various diseases.

We are analyzing the role of pro-inflammatory molecule, S100A7, in breast cancer progression and metastasis. We have shown that S100A7 is highly expressed in ER-α-negative breast carcinoma. Our laboratory has shown that S100A7 enhances breast cancer growth through modulation of pro-inflammatory and pro-metastatic pathways using a novel inducible bi-transgenic mouse model. Furthermore, we have shown that S100A7 may mediate its effects by binding to receptor for advanced glycation end products (RAGE). In addition, we have shown that S100A7 may play a differential role in ERα+ and ERα- cells. We are further analyzing the role of S100A7 in ERα+ and ERα- breast cancer, especially triple-negative, using various breast cancer mouse model systems.

We also are analyzing the role of chemokine receptor CXCR4 and its ligand, CXCL12, in breast cancer progression, angiogenesis, and metastasis. We have elucidated CXCL12-induced and CXCR4-mediated novel signaling pathways that regulate breast cancer metastasis. We are further analyzing the role of CXCL12/CXCR4/CXCR7 pathways that regulate breast cancer progression and its metastasis to various organs, such as the lungs and bones, using in vivo mouse models, including CXCL12 conditional knockout mouse models.

Our laboratory also is identifying small molecular weight anti-inflammatory molecules that have potential to be used as drugs to block breast and lung cancer growth and metastasis. In this regard, we have shown that synthetic cannabinoids, which are small molecular weight molecules and do not possess psychoactive activity, inhibit breast and lung cancer growth and metastasis in vitro and in vivo using nude mice and transgenic mouse models. We also have shown that synthetic cannabinoids that bind to cannabinoid receptors CB1 and CB2 may modulate the activity of epidermal growth factor receptor and chemokine receptor CXCR4. Our laboratory is further analyzing the CB1/CB2-mediated molecular mechanism that leads to inhibition of growth and metastasis in lung and breast cancers using various transgenic and knockout mouse models.

Our laboratory recently has shown that a novel anti-inflammatory molecule, Slit2, which binds to the Robo receptor, inhibits breast tumor growth. We have shown that the Slit2/Robo complex inhibits tumor growth by modulating the beta-catenin and CXCR4-mediated signaling pathways. In addition, we have shown that Slit2/Robo possesses anti-inflammatory properties and may modulate the tumor microenvironment. We are further characterizing the role of the Slit2/Robo complex in inhibiting breast cancer progression and metastasis through modulation of the tumor microenvironment. We also are performing structural and functional studies to determine the domain on Slit2 that possesses anti-tumorigenic activity.

In addition to regulating tumor growth, we have shown that Slit2 inhibits HIV infection. We have documented for the first time an important role for Slit2 as an inhibitor of HIV-1 replication. We have shown that Slit2 attenuated the replication of diverse clinical isolates and drug-resistant strains of HIV-1. Further elucidation of molecular mechanisms revealed that Slit2 may inhibit HIV infection by blocking viral entry through modulation of the cytoskeleton. We are further exploring the Slit2/Robo1-mediated mechanisms that block HIV entry. The above studies could facilitate the development of innovative therapeutic strategies against HIV-1 infection.

Our laboratory also is analyzing the crosstalk between chemokine receptors CXCR4/CCR5 and T cell receptor in regulating HIV. We have demonstrated a novel function of SLP-76, a key adaptor protein in the TCR signaling complex, in regulating HIV-1 release in T-cells. We are further analyzing the molecular mechanisms by which T-cell receptor regulate HIV entry and release.



Lab Members:

Jr. Faculty
Mohd Nasser
Research Scientist

Postdoctoral Research Fellows
Dinesh Ahirwar

Nagaraja Tirumuru

Nissar Wani

Graduate Students
Mohamad Elbaz

Catherine Powell

Janani Ravi

Tasha Wilkie

Helong Zhao

Undergraduate Students
Mustafa Basree
Nitin Gupta
Cory Gregory
Alexandra Ferguson
Rabee Hamed
Radhika Soni